(f) if so. the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (f) The prices of bulk drugs are fixed by this Ministry on the basis of cost-cum-technical study conducted by BICP and their examination in this Department. Government has received several reports from BICP in connection with cost-cum-technical study of bulk drugs and the prices have been fixed after examination of report of BICP which have been notified in the Gazette of India from time to time. The BICP reports are input for our decision making in the process of price fixation. These reports are confidential in nature. In regard to other details asked for, the information is too voluminous and the time and efforts required for compiling the information will not be commensurate with the results likely to be achieved.

Representations of M.Ps. against the price decontrol of Glybenclamide

1669. SHRIMATI PRATIBHA SINGH: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1656 given in the Rajya Sabha on the 1st August, 1991 and state:

(a) whether it is a fact that Government have received a number of representations from Members of Parliament against the price decontrol of Glybenclamide;

(b) if so, when each representation was received and what action has been taken on each;

(c) whether it is also a fact that sales turnover was one of the criteria of price decontrol;

(d) if so, what was the source of data of sales turnover and what are the basis of vertification of annual sales turnover of Glybenclamide;

(e) whether it is a fact that formulations of Glybenclamide has a monopoly of one company; and

(f) if so, names of the company and what is the market share enjoyed by that company?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) All such representations as have been received from Members of Parliament against the price decontrol of Glybenclamide has been considered by the Standing Committee. The matter is now under examination of the Government.

(c) Yes, Sir.

(d) The decontrol of bulk drug Glybenclamide is not based on sales turnover. The basis on which this drug has been price decontrolled is contained in the supplementary report of the Kelkar Committee, copy of which is available in the Parliament Library.

(e) and (f) M/s. Hoechst India Limited are the major formulator of bulk drug Glybenclamide. Market share of companies with regard to formulations are not monitored.

Procedures adopted by BICP

1670. KUMARI SAYEEDA KHATUN: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1654 given in the Rajya Sabha on the 1st August, 1991 and state:

(a) what is the procedure adopted by BICP to work out the prices of formulations;

(b) what is the period taken after the notification/fixation of prices of bulk drugs;

(c) what are the names of drugs based on which prices of finished medicines have not been notified within three months of the fixation of prices of bulk drugs;

(d) whether implementation of the notified prices can be held in abeyance on the ground that it requires some clarifications;

(e) if so, upto what period;

(f) what are the details of clarifications sought in regard to the reduction of prices of bulk drugs for reducing the prices of finished medicines; and

(g) what are the names of such drugs, when each clarification was sought and clarification was received?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) The procedure for fixation/revision of the prices of formulations is given in DPCO, 1987.

(b) As per para 9(2) of the DPCO, 1987 whenever the price of a bulk drug is revised. the manufacturer of the formulation has to apply to the Government for revision of prices of formulations within 30 days.

(c) to (g) The requisite information is being collected and will be laid on the Table of the House.

Higher Consumption norms for bulk Drugs

1671. SHRI SANTOSH KUMAR SAHU: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1645 given in the Rajya Sabha on the 1st August, 1991 and state:

(a) whether it is a fact that Government have noitced higher consumption norms allowed than actuals for various raw materials and services by BICP in their recommendations of prices of bulk drugs;

(b) if so, what are the details of cases where higher consumption nofms were noticed during the last awo years; and

(c) what action was taken in each case?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS & FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) BICP report is one of the inputs in fixation|revision of prices of bulk drugs. The Government ensures that optimum consumption of inputs is allowed while fixing the prices of bulk drugs.

Assessment of M|s. Hoechst due amount by Special Team

1672. SHRI SANTOSH KUMAR SAHU: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1651 given in the Rajya Sabha on the 1st August, 1991 and state:

(a) whether it is a fact that special team assessed the amount due from M|s. Hoechst for the period beyond 1983;

(b) if so, what was the amount assessed so far;

(c) whether it is a fact that Government decided at one stage that after the review is complete the responsibilities of those who indulged in corruption and omitted facts and figures would be fixed;

(d) if so, when such a decision was taken;

(e) whether it is a fact that review has been completed; and

(f) if so, what action has been taken on the decision?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (f) In view of receipt of complaints alleging acts of omission and commission on the part of the Special Team, it was decided to review the recommendations of the Special Team and the developments thereafter. As a result of that review, the tentative liability of M|s. Hoechst has been assessed at Rs. 77.81 crores. The question of taking any action against the Special Team will arise only after the liabilities are finally determined.